Is GNLX or GPCR more undervalued in 2026?

CirclFi compares Genelux Corporation (GNLX) and Structure Therapeutics Inc. (GPCR) using 13 institutional-grade valuation models. GNLX has a Quality of Company score of 5.1/10 while GPCR scores 4.1/10.

Which is a better buy — GNLX or GPCR?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GNLX and GPCR valuations compare?

GNLX at $3.05 and GPCR at $39.34 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GNLX vs GPCR Valuation Comparison 2026 — Intrinsic Value Analysis

GNLX

Pharmaceutical Preparations

Genelux Corporation

Quality

5.1

out of 10

Value Trap

LOW

Price

$3.05

Last close

Models

9/13

Active

GPCR

Pharmaceutical Preparations

Structure Therapeutics Inc.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$39.34

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	GNLX Fair Value	GNLX Upside	GPCR Fair Value	GPCR Upside
Bayesian DCF	Intrinsic	$0.87	-71.4%	$13.58	-65.5%
Earnings Power Value	Intrinsic	—	—	$20.74	-54.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.33	-89.1%	$13.69	-65.2%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GNLX vs GPCR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GNLX vs GPCR — Which Stock Is More Undervalued?

GNLX scores higher with a 5.1/10 quality rating vs GPCR's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Genelux Corporation (GNLX) and Structure Therapeutics Inc. (GPCR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GNLX currently trades at $3.05 with a QOC of 5.1/10, while GPCR trades at $39.34 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).